biostudies-literatureSCORE2-Diabetes Working Group and the ESC Cardiovascular Risk CollaborationKidney Research UKGlaxoSmithKlineBritish Heart FoundationBritish United Provident Association (BUPA) FoundationNational Institute for Health and Care Research (NIHR) Cambridge Biomedical Research CentreMedical Research CouncilNational Institute for Health Research (NIHR)Chief Scientist OfficeWellcome TrustBHF Centre of Research Excellence2544-2556https://www.ebi.ac.uk/biostudies/studies/S-EPMC10361012biostudies-literatureUnknown44(28)<h4>Aims</h4>To develop and validate a recalibrated prediction model (SCORE2-Diabetes) to estimate the 10-year risk of cardiovascular disease (CVD) in individuals with type 2 diabetes in Europe.<h4>Methods and results</h4>SCORE2-Diabetes was developed by extending SCORE2 algorithms using individual-participant data from four large-scale datasets comprising 229 460 participants (43 706 CVD events) with type 2 diabetes and without previous CVD. Sex-specific competing risk-adjusted models were used including conventional risk factors (i.e. age, smoking, systolic blood pressure, total, and HDL-cholesterol), as well as diabetes-related variables (i.e. age at diabetes diagnosis, glycated haemoglobin [HbA1c] and creatinine-based estimated glomerular filtration rate [eGFR]). Models were recalibratEuropean heart journalSCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe.PMC10361012NIHR203312JFDKcsf2/2017RE/18/1/34212SP/09/002RG/18/13/33946NIHR203769HDR-9004HDR-9005MR/L003120/1RG/13/13/30194SP/18/3/33801MC_UU_00017/3MR/R007764/1BRC-1215–20014Willeit JVolzke HWilleit PStocker HAzzopardi JRossing PSCORE2-Diabetes Working Group and the ESC Cardiovascular Risk CollaborationVardas PHageman SHJEliasson BDu YNotdurfter MTaylor OKaptoge SVlacho BTaylor JPoljicanin TPrieto-Merino DHeidemann CLavens AGillum RFGall TGraham IWalker MRHolman NBuble TVisseren FLJTilg HFumeron FUrbancic-Rovan VMagri CJHolleczek BKiechl SHalle MMauricio DDi Angelantonio ELawlor DASascha RBenedetti MMBrenner HXu ZLeitner CFranch-Nadal JTimmis AReal JVistisen DSchmidt CODorr MHerrington WStotl IMata-Cases MFerence BSattar NPennells LCarinci FBalkau BSofat RDanesh JIvanko PBonnet FDe Bacquer DSandor JJanos SScheidt-Nave CVanherwegen ASDorresteijn JANBaltane ZPildava SRead SHGualdi SSchipf SLepiksone JTibor GPristas IDale CWood ACarstensen BWild SPetitjean CHuculeci RPotier LSchottker BShi FFava SMcEvoy JWDa Providencia E Costa RBOstergaard HBSpackman SfalseSCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe.<h4>Aims</h4>To develop and validate a recalibrated prediction model (SCORE2-Diabetes) to estimate the 10-year risk of cardiovascular disease (CVD) in individuals with type 2 diabetes in Europe.<h4>Methods and results</h4>SCORE2-Diabetes was developed by extending SCORE2 algorithms using individual-participant data from four large-scale datasets comprising 229 460 participants (43 706 CVD events) with type 2 diabetes and without previous CVD. Sex-specific competing risk-adjusted models were used including conventional risk factors (i.e. age, smoking, systolic blood pressure, total, and HDL-cholesterol), as well as diabetes-related variables (i.e. age at diabetes diagnosis, glycated haemoglobin [HbA1c] and creatinine-based estimated glomerular filtration rate [eGFR]). Models were recalibrat2023-01-01T00:00:00Z2023 Jul2026-06-17T06:45:21.944Z2026-06-17T03:07:58.21ZS-EPMC103610123724733010.1093/eurheartj/ehad260